Galecto Inc. is a clinical stage biotechnology company with advanced programs in fibrosis and cancer centered on galectin-3 and LOXL2. The Company's pipeline includes an inhaled galectin-3 modulator currently in Phase 2b for the potential treatment of idiopathic pulmonary fibrosis. Galecto Inc. is headquarters in Copenhagen, Denmark.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-209.84M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.31 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -428.30% |
| Return on Assets (Trailing 12 Months) | -114.62% |
| Current Ratio (Most Recent Fiscal Quarter) | 22.49 |
| Quick Ratio (Most Recent Fiscal Quarter) | 22.48 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-110.11 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.62 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.98 |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 61.55M |
| Free Float | 61.31M |
| Market Capitalization | $1.28B |
| Average Volume (Last 20 Days) | 0.35M |
| Beta (Past 60 Months) | 1.46 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 14.20% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |